As a longtime Dexcom user who has believed this ever since my first SevenGo took my A1C from 7.3 down to 5.7 it’s nice to see research published to support my personal experience.
The headline of the article sums it up pretty well- https://www.medscape.com/viewarticle/918568
Here’s the complete article, but it’s behind a paywall- https://care.diabetesjournals.org/content/early/2019/09/10/dc19-0888
At 3 years — the longest duration of any CGM trial — real-time CGM was superior to self-monitored blood glucose (SMBG), or fingerstick, testing at least four times daily in reducing HbA1c in patients using both pumps and MDI, with little difference between the two insulin delivery modalities.
Only the Dexcom G4 or Medtronic Enlite sensors were used, not the Abbott Libre .
Only the rtCGM group had improvements in time-in-range and reduced time below range. Fewer patients using rtCGM experienced severe hypoglycemic episodes.
“It is not so important how insulin is delivered, but more important is how patients with type 1 diabetes monitor their glucose,” Šoupal said during his presentation.